Healthcare / BiotechnologyNasdaqGS
$6.91
+0.01 (+0.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-138.3M · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
0.2x
↓EV/EBITDA
N/A
•ROE
-610.7%
↓Gross Margin
91.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
-20.6%
FCF CAGR
—
FCF margin
-74.7%
FCF / Net income
-0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.4M · net income $183.5M · FCF $-4.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $6.4M | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M | $176.3M | $256.6M | $213.0M | $131.0M | $183.2M | $180.8M | $137.6M | $102.2M |
| Net Income | $183.5M | $183.5M | $-47.6M | $-284.2M | $-293.7M | $-290.0M | $-189.3M | $-77.0M | $-86.4M | $-120.9M | $-58.1M | $-85.8M | $-59.5M | $-14.9M |
| EBITDA | $-48.8M | $-48.8M | $-142.4M | $-305.2M | $-282.8M | — | — | — | — | — | — | — | — | — |
| EPS | 45.37 | 45.37 | -12.00 | -73.00 | -78.50 | -78.50 | -52.75 | — | — | — | — | — | — | — |
| Gross Margin | 91.4% | 91.4% | 47.5% | 91.5% | 85.6% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -704.1% | -704.1% | -442.1% | -662.6% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -89.5% | -27.3% | -42.9% | -36.4% | -7.8% |
| Net Margin | 2848.6% | 2848.6% | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% | -30.0% | -40.6% | -92.3% | -31.7% | -47.4% | -43.2% | -14.6% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | -0.32 | -0.73 | -4.19 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.60 | 3.60 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-4.8M | $-4.8M | $-138.3M | $-317.5M | $-184.7M | $-87.4M | $77.6M | $-84.5M | $-84.2M | $-75.0M | $5.9M | — | — | — |
| Returns | ||||||||||||||
| ROE | -610.7% | -610.7% | 21.1% | 139.2% | 1369.2% | -138.7% | -44.8% | -14.9% | -17.0% | -22.9% | -37.3% | -48.3% | -26.9% | — |
| Valuation | ||||||||||||||
| P/E | 0.15 | 0.15 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -78.3% | -78.3% | -36.7% | -66.7% | — | 33.5% | -31.3% | 20.5% | 62.6% | -28.5% | 1.3% | 31.4% | 34.7% | — |
| EPS Growth | 478.1% | 478.1% | 83.6% | 7.0% | — | -48.8% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-76.2%
EPS terminal req.
$0.61
Spread vs growth
554.3%
5Y implied EPS CAGR
-56.1%
EPS terminal req.
$0.74
Spread vs growth
534.2%
10Y implied EPS CAGR
-30.5%
EPS terminal req.
$1.19
Spread vs growth
508.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.00 → 45.37
Residual
-6.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.